SHANGHAI RENDU BIOTECHNOLOGY CO., LTD. Shanghai Rendu Biotechnology Co., Ltd. Share Price
Equities
688193
CNE1000059K5
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.04 CNY | +0.84% |
|
+9.48% | -33.42% |
| Sales 2021 | 292M 40.34M 3.36B | Sales 2022 | 304M 41.93M 3.5B | Capitalization | 1.87B 258M 21.5B |
|---|---|---|---|---|---|
| Net income 2021 | 64M 8.83M 736M | Net income 2022 | 23M 3.17M 265M | EV / Sales 2021 * | - |
| Net cash position 2021 | 194M 26.77M 2.23B | Net cash position 2022 | 819M 113M 9.43B | EV / Sales 2022 | 3.45 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
76.6
x | Employees | 529 |
| Yield 2021 * |
-
| Yield 2022 |
0.27% | Free-Float | 35.19% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.84% | ||
| 1 week | +9.48% | ||
| Current month | -8.41% | ||
| 1 month | -6.27% | ||
| 3 months | -23.50% | ||
| 6 months | -31.59% | ||
| Current year | -33.42% |
1 week
26.75
30.48
1 month
26.2434.49
Current year
22.5046.79
1 year
22.5052.63
3 years
22.5072.00
5 years
22.5072.00
10 years
22.5072.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Hui Yu
CEO | Chief Executive Officer | 41 | 01/08/01 |
Jin Liang Ju
FOU | Founder | 58 | 13/07/13 |
Ting Jiang Cai
DFI | Director of Finance/CFO | 50 | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin Liang Ju
FOU | Founder | 58 | 13/07/13 |
Yong Yi Zhang
BRD | Director/Board Member | 52 | 21/20/21 |
Wei Liang Wu
CHM | Chairman | 62 | 21/20/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 30.04 | +0.84% | 153,577 |
| 25/24/25 | 29.79 | +3.94% | 311,073 |
| 24/24/24 | 28.66 | +4.07% | 305,078 |
| 23/24/23 | 27.54 | -0.25% | 227,996 |
| 22/24/22 | 27.61 | +0.62% | 163,169 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development and sales of molecular diagnostic reagents. The Company utilizes ribonucleic acid (RNA) isothermal amplification technology to provides multiple series of diagnostic reagents, including respiration series, reproduction series, enterovirus series, blood-borne diseases series and other diagnostic reagents. The Company also designs and manufactures medical instruments. The Company mainly sells its products within domestic market.
Calendar
30/04/2024
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -33.42% | 166M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- 688193 Stock
